ClinicalTrials.gg
CompletedNCT05845567Updated Aug 16, 2024Results posted

The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)

A Phase 1 interventional study of Givinostat and Clarithromycin in Drug Drug Interaction, sponsored by Italfarmaco. Completed at 1 site in Portugal. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by Italfarmaco · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Mar 2022, registered Apr 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Primary objective:

To assess the potential effect of oral Clarithromycin on the single-dose pharmacokinetics of Givinostat.

Secondary objective:

To assess the safety and tolerability of concomitant administration of Givinostat plus Clarithromycin.

Read the detailed description

This study was planned as a phase I, open-label, 3-part, fixed-sequence, non-randomized study in healthy male and female subjects. The study (Part 2) aimed at assessing the potential effect of Clarythromycin on the single dose pharmacokynetics of Givinostat.

The total duration of Part 2 was divided as follows:

  • Screening: up to 21 days.
  • Treatment Period: Days 1 to 11.
  • Safety follow-up visit: 12±2 days.

Subjects were confined at site from Day -1 to Day 11. On Days 1 and 8, a single dose of 50 mg Givinostat, as oral suspension, was administered 1 hour after the planned morning time of Clarithromycin administration.

From Day 4 to Day 10, clarithromycin 500 mg film-coated tablets were administered twice a day, in the morning and in the evening.

The following assessments were performed:

  • Blood collection for pharmacokinetic analysis on Days 1 to 4 and 8 to 11.
  • Vital signs measurements on Days 1 and 4 to 10.
  • 12-lead ECG on Days 1, 3, 7 and 8.
  • Blood collection for laboratory tests (hematology and biochemistry) on Day 3.

Subjects were discharged in the morning of Day 11 after completing end of study procedures.

02

Conditions studied

  • Drug Drug Interaction

Keywords

  • PK
  • Pharmacokinetics
  • Givinostat
  • Clarythromycin
03

In context

Lead sponsor

Italfarmaco is the lead sponsor of 35 studies on the registry; 5 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A subject was considered eligible for the study if he/she fulfilled all the inclusion criteria:

    1. Subject's written obtained prior to any study-related procedure.
    2. Male or female subject, ≥18 and ≤55 years of age, at the time of signing the informed consent.
    3. (BMI) of 18.5 to 32.0 kg/m2 inclusive, and body weight ≥55 kg and ≤100 kg for females and body weight ≥60 kg and ≤110 kg for males.
    4. Non-smoker or ex-smoker (i.e. someone who abstained from using tobacco or nicotine-containing products for at least 3 months prior to Screening).
    5. No diseases.
    6. No major surgery within 4 weeks prior to dosing.
    7. No clinically relevant abnormalities on physical examination.
    8. No clinically relevant abnormalities on 12-lead .
    9. No clinically relevant abnormalities on clinical laboratory tests.
    10. Negative test results for anti- 1 and 2 antibodies (anti-HIV-1Ab and anti-HIV-2Ab), surface antigen (HBsAg) and anti- virus antibodies (anti-HCVAb).
    11. Female subjects are eligible if they are of non- or agree to use a non-hormonal highly effective method from 28 days prior to Screening until at least 90 days after the last study drug administration. Nonchildbearing potential female is defined as:

      1. Menopausal, i.e. no menses for ≥ 12 months without an alternative medical cause other than menopause, and a high FSH level.
      2. Pre-menopausal female with documented hysterectomy, bilateral salpingectomy and/or bilateral oophorectomy.

      A non-hormonal effective contraceptive method is defined as:

      1. Intrauterine device.
      2. Bilateral tubal occlusion.
      3. Total abstinence of heterosexual intercourse, in accordance with the lifestyle of the subject.
      4. Vasectomized partner, who has received medical assessment of the surgical success, or clinically diagnosed infertile partner.
    12. Male subjects who are sexually active with a female partner of childbearing potential (pregnant or non-pregnant) must use contraception (condom) from product administration up to at least 90 days following the last study drug administration.
    13. Male subjects must ensure that his non-pregnant female partner of childbearing potential agrees to consistently and correctly use for the same period a highly effective method of contraception (see Section 8.5.3).
    14. Male subjects must be willing not to donate sperm until 90 days following the last study drug administration.
    15. Willingness and capability to comply with the requirements of the study and ability to understand the study procedures and the risks involved.

Exclusion criteria

Exclusion Criteria

  • A subject was excluded from the study if he/she fulfilled any of the exclusion criteria:

At Screening

  1. Previous use of Givinostat.
  2. History of anaphylaxis reaction or drug reaction (e.g., angioedema, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, drug-induced hypersensitivity syndrome, druginduced neutropenia).
  3. Known history of hypersensitivity and/or allergic reactions to Givinostat, histone deacetylases (HDAC) inhibitors or to any in the formulation.
  4. History of sorbitol intolerance, sorbitol malabsorption or fructose intolerance.
  5. Any medical condition (e.g. gastrointestinal, renal or hepatic, including peptic ulcer, inflammatory bowel disease or pancreatitis) or surgical condition (e.g. cholecystectomy, gastrectomy) that may affect drug pharmacokinetics (absorption, distribution, metabolism or excretion) or subject safety.
  6. Systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 60 or over 90 mmHg, or pulse rate lower than 50 or over 100 bpm.
  7. ˃450 msec.
  8. Subjects with history of cardiac arrhythmias (documented), family history of sudden cardiac death or history of additional risk factors for torsades-depointes (e.g. heart failure, hypokalemia, long QT syndrome).
  9. Having an estimated glomerular filtration () \< 90 mL/min, based on calculation by the Cockcroft-Gault formula and normalized to an average surface area of 1.73 m2.
  10. Any of the following abnormal laboratory test values:

    1. count below the lower limit of the normal range (LLN).
    2. Total white blood cells count below the LLN.
    3. below the LLN.
    4. Triglycerides above the (ULN).
    5. Potassium or magnesium below the LLN.
  11. Positive urine alcohol, drugs-of-abuse or cotinine screen tests.
  12. Positive serum pregnancy test.
  13. If woman, she is breast-feeding.
  14. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit (i.e. more than 14 units of alcohol per week for males or more than 7 units for females).
  15. History of drug abuse within 1 year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs [such as cocaine, phencyclidine (PCP), crack, opioid derivatives including heroin, and amphetamine derivatives] within 1 year prior to screening.
  16. Participation in any clinical trial within the previous 2 months.
  17. Participation in more than 2 clinical trials within the previous 12 months.
  18. Blood donation or significant blood loss (≥ 450 mL) due to any reason or had plasmapheresis within the previous 2 months.
  19. Veins unsuitable for intravenous puncture on either arm.
  20. Difficulty in swallowing capsules, tablets or suspensions.
  21. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
  22. Known history of hypersensitivity and/or allergic reactions to clarithromycin, other macrolides or to any excipient in the formulation.

    At Admission to Treatment Period

  23. Any clinically relevant abnormalities on clinical laboratory tests.
  24. Positive urine alcohol, drugs-of-abuse or cotinine screen tests.
  25. Positive urine pregnancy test.
  26. Positive or inconclusive SARS-CoV-2 test prior to admission.
  27. Use of prescription or non-prescription medicinal products within the previous 28 days or within 5-half-lives of the medicinal product, whichever is longer.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Givinostat + Clarithromycin

    Givinostat and Clarithromycin Days 1 and 8, Givinostat 50 mg as oral suspension was administered as a single dose, 1 hour after Clarithromycin administration. From Day 4 to Day 10, Clarithromycin 500 mg film-coated tablet was administered twice a day.

    Drug: Givinostat · Drug: Clarithromycin

Interventions

  • ITF2357 Givinostat 10mg/mL. Dose: 10 mg/mL; Dosage form: oral suspension.

    Also known as: ITF2357

  • Clarithromycin 500 mg immediate-release oral film-coated tablet (Klacid®) was administered twice a day, in the morning and in the evening.

    Also known as: Klacid®

06

What researchers measure

Primary outcomes

  1. Cmax of Givinostat, Following Single Doses of the Parent Drug

    Maximum observed plasma concentration (Cmax) of givinostat. A total of 40 blood samples were collected as follows: - Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of Givinostat.

    Time frame: In the turn of 72 hours after administration of Givinostat

  2. AUC0-t of Givinostat, Following Single Doses of the Parent Drug

    AUC0-t = area under the curve from time zero to last sampling time with quantifiable concentrations. A total of 40 blood samples were collected as follows: - Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of Givinostat, on Days 1 and 8, for the determination of Givinostat.

    Time frame: In the turn of 72 hours after administration of Givinostat

  3. AUC0-inf of Givinostat, Following Single Doses of the Parent Drug

    AUC0-inf=Total AUC extrapolated to infinity, calculated as AUC0-t + Clast/λz, where Clast is the last measurable concentration and λz is the apparent terminal elimination rate constant. A total of 40 blood samples were collected as follows: - Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of givinostat.

    Time frame: In the turn of 72 hours after administration of Givinostat

  4. %AUCextrap of Givinostat, Following Single Doses of the Parent Drug

    %AUC0extrap = Percentage of AUC0-∞ due to extrapolation from the time of the last measurable concentration (tlast) to infinity, i.e., residual area, calculated as 100 ·(AUC0-∞ - AUC0-t) / AUC0-∞. A total of 40 blood samples were collected as follows: - Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of givinostat

    Time frame: In the turn of 72 hours after administration of Givinostat

  5. Tmax of Givinostat, Following Single Doses of the Parent Drug

    Tmax =The time of occurrence of maximum observed concentration of Givinostat. A total of 40 blood samples were collected as follows: - Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of Givinostat.

    Time frame: In the turn of 72 hours after administration of Givinostat

  6. λz of Givinostat, Following Single Doses of the Parent Drug

    λz is the apparent first order elimination rate constant associated with the terminal (log-linear) portion of the concentration versus time curve. The parameter is estimated by linear least square regression analysis using the last three (or more) non- zero concentrations. A total of 40 blood samples were collected as follows: - Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of givinostat

    Time frame: In the turn of 72 hours after administration of Givinostat

  7. t1/2 of Givinostat, Following Single Doses of the Parent Drug

    t1/2 is the apparent terminal elimination half-life, calculated as ln(2)/λz. A total of 40 blood samples were collected as follows: - Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of Givinostat.

    Time frame: In the turn of 72 hours after administration of Givinostat

Secondary outcomes

  1. Severity of Treatment Emergent Adverse Events (TEAE)

    An AE was considered as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily imply a causal relationship with this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The period of observation for the collection of medical occurrences extended from the time when the subject gave Informed Consent until the follow-up visit.

    Time frame: Throughout the study and 10-14 days after the EoS (follow-up visit), i.e. up to day 30-34

07

Results

Posted Feb 9, 2024

Participant flow

20 patients were enrolled. One discontinued after first dosing, so while safety and PK analysis populations were composed of 20 subjects, the drug-drug interaction comparable bioavailability is calculated on 19 subjects.

Participant flow — Overall Study
MilestoneTotal Subjects Enrolled
Started20
Safety analysis population20
Pk analysis population20
Drug-drug interaction comparable bioavailability19
Completed19
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryCmax of Givinostat, Following Single Doses of the Parent Drug

Maximum observed plasma concentration (Cmax) of givinostat. A total of 40 blood samples were collected as follows: - Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of Givinostat.

Time frame:
In the turn of 72 hours after administration of Givinostat
Reported as:
Geometric mean · ng/mL
Cmax of Givinostat, Following Single Doses of the Parent Drug
ng/mLGivinostat Alone (Day 1)Givinostat Co-Administered With Clarithromycin (Day 8)
Cmax of Givinostat, Following Single Doses of the Parent Drug53.57 ± 24.275.35 ± 21.9
Statistical analysis
  • Givinostat Alone (Day 1) vs Givinostat Co-Administered With Clarithromycin (Day 8) · Ratio of the geometric lsmeans: 139.43 · 90% CI 129.73 to 149.86
PrimaryAUC0-t of Givinostat, Following Single Doses of the Parent Drug

AUC0-t = area under the curve from time zero to last sampling time with quantifiable concentrations. A total of 40 blood samples were collected as follows: - Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of Givinostat, on Days 1 and 8, for the determination of Givinostat.

Time frame:
In the turn of 72 hours after administration of Givinostat
Reported as:
Geometric mean · ng.h/mL
AUC0-t of Givinostat, Following Single Doses of the Parent Drug
ng.h/mLGivinostat Alone (Day 1)Givinostat Co-Administered With Clarithromycin (Day 8)
AUC0-t of Givinostat, Following Single Doses of the Parent Drug344.67 ± 20.4406.61 ± 13.0
Statistical analysis
  • Givinostat Alone (Day 1) vs Givinostat Co-Administered With Clarithromycin (Day 8) · Ratio of the geometric lsmeans: 117.97 · 90% CI 112.24 to 124.00
PrimaryAUC0-inf of Givinostat, Following Single Doses of the Parent Drug

AUC0-inf=Total AUC extrapolated to infinity, calculated as AUC0-t + Clast/λz, where Clast is the last measurable concentration and λz is the apparent terminal elimination rate constant. A total of 40 blood samples were collected as follows: - Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of givinostat.

Time frame:
In the turn of 72 hours after administration of Givinostat
Reported as:
Geometric mean · ng.h/mL
AUC0-inf of Givinostat, Following Single Doses of the Parent Drug
ng.h/mLGivinostat Alone (Day 1)Givinostat Co-Administered With Clarithromycin (Day 8)
AUC0-inf of Givinostat, Following Single Doses of the Parent Drug349.25 ± 20.1411.69 ± 12.7
Statistical analysis
  • Givinostat Alone (Day 1) vs Givinostat Co-Administered With Clarithromycin (Day 8) · Ratio of the geometric lsmeans: 117.88 · 90% CI 112.13 to 123.92
Primary%AUCextrap of Givinostat, Following Single Doses of the Parent Drug

%AUC0extrap = Percentage of AUC0-∞ due to extrapolation from the time of the last measurable concentration (tlast) to infinity, i.e., residual area, calculated as 100 ·(AUC0-∞ - AUC0-t) / AUC0-∞. A total of 40 blood samples were collected as follows: - Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of givinostat

Time frame:
In the turn of 72 hours after administration of Givinostat
Reported as:
Geometric mean · percentage of AUC0-∞
%AUCextrap of Givinostat, Following Single Doses of the Parent Drug
percentage of AUC0-∞Givinostat Alone (Day 1)Givinostat Co-Administered With Clarithromycin (Day 8)
%AUCextrap of Givinostat, Following Single Doses of the Parent Drug1.28 ± 23.31.17 ± 29.7
PrimaryTmax of Givinostat, Following Single Doses of the Parent Drug

Tmax =The time of occurrence of maximum observed concentration of Givinostat. A total of 40 blood samples were collected as follows: - Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of Givinostat.

Time frame:
In the turn of 72 hours after administration of Givinostat
Reported as:
Median · hours
Tmax of Givinostat, Following Single Doses of the Parent Drug
hoursGivinostat Alone (Day 1)Givinostat Co-Administered With Clarithromycin (Day 8)
Tmax of Givinostat, Following Single Doses of the Parent Drug2.00 (1.00 to 4.00)1.50 (0.50 to 2.50)
Primaryλz of Givinostat, Following Single Doses of the Parent Drug

λz is the apparent first order elimination rate constant associated with the terminal (log-linear) portion of the concentration versus time curve. The parameter is estimated by linear least square regression analysis using the last three (or more) non- zero concentrations. A total of 40 blood samples were collected as follows: - Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of givinostat

Time frame:
In the turn of 72 hours after administration of Givinostat
Reported as:
Geometric mean · 1/hour
λz of Givinostat, Following Single Doses of the Parent Drug
1/hourGivinostat Alone (Day 1)Givinostat Co-Administered With Clarithromycin (Day 8)
λz of Givinostat, Following Single Doses of the Parent Drug0.112 ± 4.90.103 ± 23.2
Primaryt1/2 of Givinostat, Following Single Doses of the Parent Drug

t1/2 is the apparent terminal elimination half-life, calculated as ln(2)/λz. A total of 40 blood samples were collected as follows: - Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of Givinostat.

Time frame:
In the turn of 72 hours after administration of Givinostat
Reported as:
Geometric mean · hours
t1/2 of Givinostat, Following Single Doses of the Parent Drug
hoursGivinostat Alone (Day 1)Givinostat Co-Administered With Clarithromycin (Day 8)
t1/2 of Givinostat, Following Single Doses of the Parent Drug6.18 ± 4.96.70 ± 23.0
SecondarySeverity of Treatment Emergent Adverse Events (TEAE)

An AE was considered as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily imply a causal relationship with this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The period of observation for the collection of medical occurrences extended from the time when the subject gave Informed Consent until the follow-up visit.

Time frame:
Throughout the study and 10-14 days after the EoS (follow-up visit), i.e. up to day 30-34
Reported as:
Number · number of events
Severity of Treatment Emergent Adverse Events (TEAE)
number of eventsGivinostatClarithromycinTotal Enrolled
mild434143
moderate303
severe000
total464146

Adverse events

Collected over Throughout the study and 10-14 days after the End of Study (follow-up visit), i.e. up to day 30-34, all TEAEs, considered related or not related to IMPs, were collected.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Givinostat0/20 (0%)0/20 (0%)16/20 (80%)
Clarithromycin0/19 (0%)0/20 (0%)16/19 (84.2%)
Total Enrolled0/20 (0%)0/20 (0%)16/20 (80%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventGivinostatClarithromycinTotal Enrolled
Dry skinSkin and subcutaneous tissue disorders8/207/198/20
Abdominal painGastrointestinal disorders4/204/194/20
FlatulenceGastrointestinal disorders4/204/194/20
HeadacheNervous system disorders4/204/194/20
Abdominal pain upperGastrointestinal disorders2/202/192/20
Blood thyroid stimulating hormone increasedInvestigations2/202/192/20
MigraineNervous system disorders2/202/192/20
Back painMusculoskeletal and connective tissue disorders2/201/192/20
NauseaGastrointestinal disorders1/201/191/20
Vessel puncture site haemorrhageGeneral disorders1/201/191/20

Baseline characteristics

Twenty (20) subjects received at least one dose of an IMP in the study. They constitute the Safety Analysis Population.

Age, Categorical
Age, Categorical(Participants)Total Subjects Enrolled
<=18 years0
Between 18 and 65 years20
>=65 years0
Age, Continuous
Age, Continuous(years)Total Subjects Enrolled
Mean31 ± 5.7
Sex: Female, Male
Sex: Female, Male(Participants)Total Subjects Enrolled
Female7
Male13
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Total Subjects Enrolled
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White14
More than one race6
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Total Subjects Enrolled
Portugal20
08

Study locations

1 site
  • Hospital da Prelada, 3rd Floor & East Wing 4th Floor Rua Sarmento de Beires
    Porto, 153, Portugal
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in May 2022, 1 month.

Results were first posted in Feb 2024, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2023
First posted
May 6, 2023
StartActual
Mar 21, 2022
Primary completionActual
May 8, 2022
CompletionActual
May 24, 2022
Results first posted
Feb 9, 2024
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05845567
Lead sponsor
Italfarmaco
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Mar 21, 2022
Primary completion
May 8, 2022
Completion
May 24, 2022
Results posted
Feb 9, 2024
Last update
Aug 16, 2024

Study contacts

Marlene Fonseca, MD
principal investigator · Blueclinical, Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Givinostat · Clarithromycin

Start the discussion